Sourasky Medical Center (Ichilov)
Sourasky Medical Center (Ichilov)
Israël, Tel Aviv
Ofer Merimsky
41 années d'expérience
accréditations :
La clinique est certifiée :
Le retrait d'un cancer du foie en Israël coûte généralement entre $22,000 et $40,000. Le tarif final dépend de la technique chirurgicale, de la taille de la tumeur et de la ville. Les principaux centres se situent à Tel-Aviv, Jérusalem et Haïfa. En France, les patients paient en moyenne $35,000 pour ces interventions. Choisir Israël permet une économie moyenne de 37 %. Ce budget inclut les examens préopératoires, les honoraires du chirurgien, l'anesthésie et un séjour de 5 à 10 jours.
Avis d'expert Bookimed : Consulter un spécialiste comme le Dr Menahem Ben-haim au centre Sourasky garantit une expertise reconnue par Forbes. Si les cliniques de Tel-Aviv affichent des tarifs plus élevés, elles offrent un taux de succès oncologique de 90 %. Des centres comme Assuta permettent de choisir son chirurgien. Cette flexibilité assure des soins de qualité dans des établissements accrédités JCI, sans les longs délais d'attente habituels.
Pourquoi les patients choisissent-ils Israël pour l'ablation du cancer du foie ?
Accédez à des solutions avancées pour l'ablation du cancer du foie dans des cliniques de confiance .
| Israël | Turquie | Espagne | |
| Élimination du cancer du foie | de $22,000 | de $10,800 | de $35,000 |
| Thérapie SIRT | de $24,500 | de $24,000 | de $32,000 |
| Résection hépatique | de $27,500 | de $11,700 | de $35,000 |
Chef de l'Unité d'Oncologie des Tissus Mous et Osseuse au Centre Médical Sourasky – Le Professeur Merimsky est spécialisé dans les cas complexes de cancer du foie.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Prof. Ido Nachmany heads the Second Surgical Department at Sheba Medical Center. He specializes in HPB and robotic surgery for diseases of the liver, pancreas, and bile ducts, and for gastrointestinal neuroendocrine tumors. He also performs adrenal, spleen, and stomach surgery. Forbes listed him among Israel’s top physicians.
He advances minimally invasive robotic and laparoscopic techniques. The aim is better precision and faster recovery.
Credentials: Senior Lecturer at Tel Aviv University. Member of ASTS and IHPBA. Completed HPB and abdominal transplant fellowships at the Thomas E. Starzl Transplantation Institute. Board certified in General Surgery (Israel), Abdominal Organ Transplantation (ASTS), and HPB Surgery (University of Pittsburgh). He has published in Cancer Research, the Journal of the American College of Surgeons, and the European Journal of Surgical Oncology.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.